Samplimy wins Money Talks Pitch Competition: aiming to transform the future of sampling

With a technology that enables painless and more accessible sampling, Samplimy took home first prize in the Money Talks Pitch Competition at the second Life Science Fair Flemingsberg of the year.

The medtech company develops solutions for microsampling, where biomarkers* are collected through painless methods directly from the skin. The technology is based on more than five years of research at KTH Royal Institute of Technology, and makes it possible for patients to collect samples of both blood and interstitial fluid (ISF)* themselves – without the use of traditional needles or the need to visit a clinic.

Samplimy is about unlocking access to biodata at frequency and scale by providing patient-centric sampling of blood and interstitial fluid. Today, clinical trials are expensive due to complex logistics and patients struggling with painful blood collection and repeated clinic visits. Our technology enables self-sampling that you barely notice, allowing for more time points and richer real-world data needed for the revolution we see in omics and AI models to deliver entirely new insights. In addition, microsampling can open the door to diagnostics for large parts of the global population currently lacking basic access, with the goal of facilitating healthcare’s shift toward more preventive and predictive care, says CEO Patrik Nilsson.

Their first product, which focuses on ISF and is aimed at researchers and life science companies within dermatology and skincare, is already being used in research studies and pilot projects. The latter for example together with Procter & Gamble in the US. At the same time, the company is also developing a blood-based product, with the aim of enabling more patient-friendly and decentralized clinical studies and screening programs.

Looking ahead, Samplimy’s focus is on scaling up the organization and product development, expanding ongoing collaborations and pilot studies, and initiating new studies. The win in the Money Talks Pitch Competition they view as a positive step in going forward.

The win means a lot, both as a stamp of quality and as confirmation that colleagues, investors, and the market see the same needs that we do – and that the hard work we put in is truly relevant”, says Patrik.

 

Interstitial fluid is the fluid found between cells in the body’s tissues and serves as a local source of information about what is happening in the body, where it happens.

Biomarkers are measurable indicators in the body that can provide information about health or disease.

AlzeCure Pharma – a hope in the fight against Alzheimer’s

Neurological diseases and the pain area are struggling with great medical needs, including the lack of broad-spectrum drugs. Those are gaps in the market that AlzeCure Pharma wants to fill, and they are well on their way. They recently received a grant from the European Innovation Council (EIC) to finance a clinical phase 2 study of the drug candidate NeuroRestore ACD856 for Alzheimer’s disease.

Kick-off Cluster Engine Life Science Flemingsberg!

At the end of last year, the Flemingsberg Science Foundation was granted funding from the European Regional Development Fund (ERDF) for the project Cluster Engine Life Science Flemingsberg, which aims to strengthen the growth and establishment of small and medium-sized enterprises (SMEs) within the life science sector in the Stockholm region. Recently, it was time for the official launch – and what a grand launch it was!

Flemingsberg Expands with Huge Bostäder

Imagine a home where The Royal Swedish Opera and The Royal Dramatic Theatre’s studios are in your front yard, and the Flemingsberg Forest Nature Reserve and Lake Gömmaren are in your back yard. Where Campus Flemingsberg is your neighbor to the left, and a modernized shopping center your neighbor to the right. Too good to be true? Not at all!

Go to Top